Seattle Genetics Highlights Data for Adcetris plus CHP in PTCL Patients

The biopharmaceutical is highlighting data it will present at the European Society for Medical Oncology Congress this weekend in Madrid.

Seattle Genetics will present data constituting an updated two-year durability analysis from a phase I trial testing its antibody drug conjugate Adcetris along with combination chemotherapy in patients with newly diagnosed, CD30 positive, peripheral T-cell lymphoma (PTCL).

In the trial patients received Adcetris coupled with what is considered standard treatment for PTCL, notably, either the CHOP chemotherapy regimen (A+CHOP), or CHP (A+CHP, CHOP minus vincristine).

Since PTCL is such a broad category, there was bound to be variations in the recruited patients, and indeed among the 26 patients:

  • Nineteen have systemtic anaplastic large cell lymphoma (sALCL)
  • Of those nineteen, sixteen have ALK-negative disease, associated with significantly poorer prognoses
  • Seven patients with other unnamed types of PTCL

So the updated findings include the following, based on a median observation time of 27.1 months and involving those receiving A+CHP:

  • Estimated 2 year progression-free survival rate is 54 percent; no progression events to report since they first reported data on this trial at the ASH meeting about ten months ago
  • Estimated 2 year overall survival rate is 80 percent
  • Common side effects, occurring in over 40 percent of patients: peripheral sensory neuropathy, nausea, fatigue, hair loss, diarrhea, shortness of breath

Seattle Genetics has already begun recruiting for a pivotal phase III randomized, double-blind, placebo-controlled trial pitting A+CHP against CHOP as front-line treatment in this patient population.

Source: Seattle Genetics

More Articles

More Articles

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...

Secondary cancers are cancers that develop as a result of chemotherapy and/or...

One of the greatest fears of lymphoma survivors is that they’ll relapse and have to undergo treatment again. This fear is normal but awful to...

Over the years, various classification systems have been used to differentiate lymphoma types including the Rappaport Classification (used until...

If you are new to this website or are looking for guidance to a specific page, here is a list of links to articles that can help you. The "Main...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...